Delirium is a serious mental disorder, which can cause two most common type of behaviors, namely, hyperactive behavior, which is characterized by severe confusion, disorientation and disturbance in consciousness that fluctuates and hypoactive behavior, which is characterized by the sudden onset of withdrawal from interaction with the outside world. This serious mental disorder is mainly caused due to physical or mental illnesses, which is temporary and reversible in most of the cases. Major symptoms include clouding of consciousness, disorientation of thoughts, illusions, hallucinations, fluctuating levels of consciousness, dysphasia, dysarthria, tremors, asterixis in hepatic encephalopathy and uremia. Some major factors that cause delirium are withdrawal from alcohol or sedatives, drug abuse, chemical disturbances within the body, infections, strokes, dementia, poisoning and surgeries.
Browse the full report with request TOC at http://www.transparencymarketresearch.com/delirium-market.html
Major driving factors for the growth of this market include, increasing prevalence of various neurological disorders worldwide, rising number of cases of physical and mental illnesses, increasing prevalence of cardiovascular diseases and rising demand for advanced therapeutics. The world is experiencing a shift in the population suffering from mental disorders, which is increasing at a rapid rate due to various factors like brain and heart related problems, related surgeries, alcohol or other drug abuse etc. These will help drive the demand for new and advanced therapeutics for delirium treatment. Thus, above factors will drive the growth of this market in future.
Buy This Report with 10% Discount and Customize as per Your Requirement @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2339
Geographically, North America dominates the delirium market followed by the European market. Some of the major factors responsible for these regions’ dominance are their high awareness levels about the disease and its available treatments and their affordability. However, Asia-Pacific is the most lucrative market as this region is showing the fastest growth due to increasing incidences of the disease and growing healthcare awareness as well. Some of the key players operating in this market are Air Liquide Sante International, Asklepios Kliniken GmbH, Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Hospira, Inc., Novartis AG, Pfizer, Inc., andRegenstrief Institute, Inc.